First, we investigated regional alterations of microglial activity, Aβ, tau, perfusion, and GMV in our cohort of primary (4RT) and secondary (typical AD, AD-CBS) tauopathies at the group level. This evidence concerns the gene MAPT and Alzheimer disease.